Anticoagulation Strategy for Mitral Valve Replacement

Mechanical Mitral Valve Replacement

The American College of Cardiology recommends warfarin as the cornerstone of therapy, targeting an INR of 3.0, which is higher than the 2.5 target for mechanical aortic valves, due to the greater thrombotic risk associated with mechanical mitral prostheses 1, 2, 3
The American Heart Association states that vitamin K antagonists (VKA) are the only proven anticoagulants for mechanical valves, and direct oral anticoagulants (DOACs) like dabigatran are contraindicated due to increased thrombotic and bleeding complications 1, 2
Adding aspirin 75-100 mg daily to warfarin may be considered (Class IIb recommendation) when the patient has low bleeding risk, according to the American College of Cardiology 1, 2, 5
The 2014 ACC/AHA guidelines recommend aspirin 75-100 mg daily in addition to VKA therapy for all mechanical valves, with a Class I, Level A recommendation 6, 7

The American College of Cardiology suggests that aspirin 75-100 mg daily is reasonable for all patients with bioprosthetic mitral valves who have no other indication for anticoagulation 1, 2, 8
For patients at low bleeding risk, warfarin to achieve INR 2.5 is reasonable for at least 3 months and up to 6 months after surgical replacement, according to the American Heart Association 1, 2
After the initial period, transition to aspirin monotherapy is recommended, with a target dose of 75-100 mg daily 4
If additional risk factors exist (atrial fibrillation, previous thromboembolism, left ventricular dysfunction, hypercoagulable state), warfarin with INR 2.0-3.0 is indicated rather than aspirin alone, as stated by the American College of Cardiology 9, 4

For mechanical mitral valve replacement, the American College of Cardiology recommends starting warfarin targeting INR 3.0, assessing bleeding risk factors, and considering adding aspirin 75-100 mg daily if bleeding risk is low 1, 2, 6
For bioprosthetic mitral valve replacement, the American Heart Association suggests warfarin INR 2.5 for the first 3-6 months if low bleeding risk, otherwise aspirin 75-100 mg, and then aspirin 75-100 mg daily after 3-6 months if no other anticoagulation indication 1, 4, 8

The American College of Cardiology states that direct oral anticoagulants (DOACs) are contraindicated for mechanical valves due to increased thrombotic and bleeding complications 1, 2
The American Heart Association recommends targeting INR 3.0 for mechanical mitral valves, as lower targets may not provide sufficient anticoagulation intensity 1, 4